期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺导管内癌和浸润性导管癌中骨桥蛋白的表达及意义 被引量：2

Expression of osteopontin in breast intraductal carcinoma and infiltrating ductal carcinoma and its clinical significance
下载PDF
导出
摘要 目的探讨正常乳腺组织、乳腺导管内癌和浸润性导管癌中骨桥蛋白(osteopontin,OPN)的表达及临床意义。方法应用免疫组化S-P法测定OPN在正常乳腺组织、乳腺导管内癌和浸润性导管癌中的表达,采用SPSS 13.0软件进行统计学分析。结果正常乳腺组织、乳腺导管内癌、浸润性导管癌OPN的阳性表达率分别为0%(0/20)、20.0%(5/25)、43.1%(25/58),组间差异有统计学意义(P<0.05)。有否家族史、不同年龄、不同原发肿瘤大小的浸润性导管癌患者间OPN的表达差异无统计学意义,但不同组织学分级、不同临床TNM分期、腋窝淋巴结转移与否患者间OPN的表达差异有统计学意义(P<0.05)。结论 OPN可能参与了乳腺癌的发生、发展和转移,有利于乳腺癌的预后判断。 Objective To investigate the expression of osteopontin（OPN） in normal breast epithelium,intraductal carcinoma and infiltrating ductal carcinoma and its clinical significance.Methods The expression of OPN was examined by S-P immunohistochemistry in all specimens,and the results were statistically analyzed.Results The positive rates of OPN in normal breast epithelium,intraductal carcinoma and infiltrating ductal carcinoma specimens were 0%（0 /20）,20.0%（5 /25） and 43.1%（25 /58）,respectively,with significant differences found between the latter two groups（P 0.05）.OPN expression in breast infiltrating ductal carcinoma was not correlated with the family history,the sizes of primary tumor or patient ages,and it was correlated with histological types,clinical TNM stages and axillary lymphatic metastasis（P 0.05）.Conclusion OPN may participate in the development,progression,metastasis of breast cancer,and it may be used for predicting the prognosis of breast cancer.
作者 李曦洲 隋金珂 谢轶群 施俊义
机构地区 第二军医大学长海医院甲乳外科
出处 《第二军医大学学报》 CAS CSCD 北大核心 2011年第1期49-52,共4页 Academic Journal of Second Military Medical University
关键词 乳腺肿瘤 非浸润性导管内癌 浸润性导管癌 免疫组织化学 骨桥蛋白质 breast neoplasms noninfiltrating intraductal carcinoma infiltrating ductal carcinoma immunohistochemistry ostepontin
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Tse G M,Tan P H,Cheung H S,Cbu W C,Lam W W. Inter mediate to highly suspicious calcification in breast lesions: a ra dio pathologic correlation[J].Breast Cancer Res Treat, 2008 110,1- 7.
  • 2Soares R, Balogh G, Guo S, Gartner F, Russo J, Schmitt F. Evi dence for the notch signaling pathway on the role of estrogen in angiogenesis[J]. Mol Endocrinol, 2004,18 : 2333- 2343.
  • 3Weber G F. The metastasis gene osteopontin: a candidate tar get for cancer therapy[J].Biochim Biophys Acta, 2001,1552: 61-85.
  • 4Reinholz M M, hurria S J,lngle J N,Roche P C. Differential gene expression of TGF beta family members and osteopontin in breast tumor tissue: analysis by real time quantitative PCR [J].Breast Cancer Res Treat,2002,74:255- 269.
  • 5Hedley B D,Welch D R, Allan A L, AI Katib W, Dales D W, Postenka C O,et al. Downregulation of osteopontin contributes to melastasis suppression by breast cancer metastasis suppres sot 1[J]. Int J Cancer,2008,123:526- 534.
  • 6Fisher J L,Field C L,Zhou H, Harris T L, Henderson M A, Choong P F. Urokinase plasminogen activator system gene exmetastases-a comparison of normal breast tissue,non invasive and invasive carcinoma and osseous metastases [J]. Breast Cancer ices Treat,2000,61:1-12.
  • 7Dai J ,Peng L, Fan K, Wang H, Wei R, Ji G, et al. Ostcopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells [J].Oncogene, 2009, 28:3412- 3422.
  • 8Allan A L,George R,Vantyghem S A, Lee M W, Hodgson N C,Engel C J, et al. Role of the integrin-binding protein os teopontin in lymphatic melastasis of breast cancer[J]. Am J Pathol,2006,169:233- 246.
  • 9Singhal H,Bautista D S,Tonkin K S,O'Malley F P,Tuck A B, Chambers A F, et al. Elevated plasma osteoponlin in metastatic breast cancer associated with increased tumor burden and de creased survival[J]. Clin Cancer Res,1997,3:605 -511.
  • 10Guarino V, Faviana P, Salvatore G, Castellone M D, Cirafici A M,De Falco V, et al. Osteopontin is overcxpressed in human Dapillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness[J]. J Clin Endocrinol Metab, 2005,90:5270 -5278.

同被引文献23

  • 1钱秀珍.乳腺导管内癌22例诊治分析[J].苏州大学学报（医学版）,2006,26(5):861-862. 被引量：3
  • 2Tang Y, Xu F, Tao K, et al. Clinical applications of sentinel lymph node biopsy in ductal carcinoma in situ of the breast: a dilemma[J]. Tohoku J Exp Med, 2011, 224(1):1-5.
  • 3Han JS, Molberg KH, Sarode V. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases[J]. Breast J,2011,17(3) :223 -229.
  • 4Rittling S R, Chambers A F. Role of osteopontin in tumor progres- sion [ J ]. Br J Cancer, 2004,90 ( 10 ) : 1877 - 81.
  • 5Chen C, Xia H S, Gong Y P, et al. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis [ J ]. Bio- materials, 2010,31 (33) :8818 - 25.
  • 6E1-Tanani M K, Campbell F C, Kurisetty V, et al. The regulation and role of osteopontin in malignant transformation and cancer[ J ]. Cytokine Growth Factor Rev, 2006,17 (6) :463 -74.
  • 7Tuck A B, Chambers A F, Allan A L, et al. Osteopontin overex- pression in breast cancer: knowledge gained and possible implica- tions for clinical management [ J]. J Cell Biochem, 2007, 102 (4) :859 -68.
  • 8Ribeiro-Silva A, Oliveira da Costa J P. Osteopontin expression ac- cording to molecular profile of invasive breast cancer: a clinico- pathological and immunohistochemical study[ J]. Int J Biol Mark- ers, 2008,23(3) :154 -60.
  • 9Patani N, Jouhra F, Jiang W, et al. Osteopontin expression pro- files predict pathological and clinical outcome in breast cancer [ J]. Anticancer Res, 2008,28 (6B) :4105 - 10.
  • 10Wang X, Chao L, Ma G, et al. Increased expression of osteopon- tin in patients with triple-negative breast cancer [ J]. Eur J ClinInvest, 2008,38(6) :438 -46.

引证文献2

二级引证文献3

第二军医大学学报
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部